Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Status:
Closed
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
NCT#03698019
S1801 is permanently closed to accrual, effective May 5, 2022, at 11:59pm Pacific Time.
